Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

246
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
246
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

418
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
418
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

301
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
301
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

361
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
361
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum neurofilament light chain (sNFL) as a predictive biomarker for Chemotherapy-induced peripheral neurotoxicity (CIPN): consideration of current evidence, validation steps, and barriers to CIPN biomarker implementation in clinical practice-a narrative review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Lipidomic Predictors of Paclitaxel-Induced Peripheral Neuropathy.

JCO precision oncology·2026
Same author

Importance of and Strategies for Implementing <i>DPYD</i> Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer.

JAMA network open·2026
Same author

Identification of additional DPYD polymorphisms that increase the risk of severe fluoropyrimidine toxicity and improved predictive accuracy when combined with previously validated variants.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The role of uridine diphosphate glucuronosyltransferase 1A4 polymorphisms on posaconazole exposure.

Pharmacogenetics and genomics·2026
Same journal

Endothelial Cell Phenotypic Plasticity in Atherosclerosis.

Handbook of experimental pharmacology·2026
Same journal

Endothelial Dysfunction and Neurovascular Alterations in Autism Spectrum Disorder.

Handbook of experimental pharmacology·2026
Same journal

Molecular Mechanisms of Endothelial Shear Stress Mechanotransduction in Health and Disease.

Handbook of experimental pharmacology·2026
Same journal

Microvasculature of the Pancreatic Islets of Langerhans in Health and Diabetes.

Handbook of experimental pharmacology·2026
Same journal

Mechanisms of Actions of Physiological, Pharmacological, and Toxicological Dietary Bioactive Inorganic Boron.

Handbook of experimental pharmacology·2026
Same journal

BNCT Plus Luminescence: New Paradigm for Boron-Containing Drug Design.

Handbook of experimental pharmacology·2026
See all related articles

Related Experiment Video

Updated: Aug 25, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.3K

Chemotherapy-Induced Peripheral Neuropathy.

Ciao-Sin Chen1, Daniel L Hertz2

  • 1Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.

Handbook of Experimental Pharmacology
|October 17, 2022
PubMed
Summary
This summary is machine-generated.

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect impacting cancer treatment. Metabolomics research identifies potential biomarkers like histidine and phenylalanine for early detection and targeted therapies.

Keywords:
ChemotherapyHistidineMetabolomicsPeripheral neuropathyPhenylalanine

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.5K
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.0K

Related Experiment Videos

Last Updated: Aug 25, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.3K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.5K
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.0K

Area of Science:

  • Oncology
  • Neurology
  • Metabolomics

Background:

  • Chemotherapy-induced peripheral neuropathy (CIPN) is a significant adverse effect of anti-cancer drugs, often necessitating treatment adjustments and impacting patient quality of life.
  • The underlying mechanisms of CIPN remain incompletely understood, highlighting the need for reliable biomarkers to identify at-risk individuals and potential therapeutic targets.

Purpose of the Study:

  • To review existing metabolomics studies focused on CIPN.
  • To identify metabolic pathways and potential biomarkers implicated in CIPN.
  • To explore the relevance of these pathways in other forms of peripheral neuropathy.

Main Methods:

  • Systematic review of published metabolomics research concerning CIPN.
  • Cross-referencing identified CIPN metabolites and pathways with findings from studies on other neuropathies (e.g., diabetic neuropathy).

Main Results:

  • Six potential biomarkers for CIPN were identified through the review.
  • Histidine and phenylalanine emerged as key biomarkers with established roles in neurotransmission and neuroinflammation relevant to peripheral neuropathy.

Conclusions:

  • Metabolomics offers a promising approach to understanding and potentially diagnosing CIPN.
  • Further large-scale clinical studies are crucial for validating identified CIPN metabolomic biomarkers and advancing therapeutic strategies.